Filtered By:
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 39664 results found since Jan 2013.
Early 3 ‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Exp Ther Med. 2023 Aug 9;26(4):462. doi: 10.3892/etm.2023.12161. eCollection 2023 Oct.ABSTRACTRemdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progress...
Source: Experimental and Therapeutic Medicine - September 4, 2023 Category: General Medicine Authors: Vasiliki Epameinondas Georgakopoulou Aikaterini Gkoufa Sotiria Makrodimitri Dimitrios Basoulis Aristeidis Tsakanikas Georgios Karamanakos Elpida Mastrogianni Pantazis M Voutsinas Demetrios A Spandidos Chrysovalantis V Papageorgiou Maria N Gamaletsou Nikol Source Type: research
Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients
CONCLUSIONS: Low anti-spike IgG levels after third vaccination in kidney transplant recipients were associated with symptomatic breakthrough infection and, particularly, with hospitalization during the Omicron surge. These data can be used to identify patients requiring additional protective measures, such as passive immunization using monoclonal antibodies.PMID:37665287 | PMC:PMC10485855 | DOI:10.3343/alm.2024.44.1.64
Source: Annals of Laboratory Medicine - September 4, 2023 Category: Laboratory Medicine Authors: Ahram Han Sangil Min Eun-Ah Jo Hajeong Lee Yong Chul Kim Seung Seok Han Hee Gyung Kang Yo Han Ahn Inseong Oh Eun Young Song Jongwon Ha Source Type: research
Early 3 ‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Exp Ther Med. 2023 Aug 9;26(4):462. doi: 10.3892/etm.2023.12161. eCollection 2023 Oct.ABSTRACTRemdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progress...
Source: Experimental and Therapeutic Medicine - September 4, 2023 Category: General Medicine Authors: Vasiliki Epameinondas Georgakopoulou Aikaterini Gkoufa Sotiria Makrodimitri Dimitrios Basoulis Aristeidis Tsakanikas Georgios Karamanakos Elpida Mastrogianni Pantazis M Voutsinas Demetrios A Spandidos Chrysovalantis V Papageorgiou Maria N Gamaletsou Nikol Source Type: research
Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients
CONCLUSIONS: Low anti-spike IgG levels after third vaccination in kidney transplant recipients were associated with symptomatic breakthrough infection and, particularly, with hospitalization during the Omicron surge. These data can be used to identify patients requiring additional protective measures, such as passive immunization using monoclonal antibodies.PMID:37665287 | PMC:PMC10485855 | DOI:10.3343/alm.2024.44.1.64
Source: Annals of Laboratory Medicine - September 4, 2023 Category: Laboratory Medicine Authors: Ahram Han Sangil Min Eun-Ah Jo Hajeong Lee Yong Chul Kim Seung Seok Han Hee Gyung Kang Yo Han Ahn Inseong Oh Eun Young Song Jongwon Ha Source Type: research
Early 3 ‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Exp Ther Med. 2023 Aug 9;26(4):462. doi: 10.3892/etm.2023.12161. eCollection 2023 Oct.ABSTRACTRemdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progress...
Source: Experimental and Therapeutic Medicine - September 4, 2023 Category: General Medicine Authors: Vasiliki Epameinondas Georgakopoulou Aikaterini Gkoufa Sotiria Makrodimitri Dimitrios Basoulis Aristeidis Tsakanikas Georgios Karamanakos Elpida Mastrogianni Pantazis M Voutsinas Demetrios A Spandidos Chrysovalantis V Papageorgiou Maria N Gamaletsou Nikol Source Type: research
Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients
CONCLUSIONS: Low anti-spike IgG levels after third vaccination in kidney transplant recipients were associated with symptomatic breakthrough infection and, particularly, with hospitalization during the Omicron surge. These data can be used to identify patients requiring additional protective measures, such as passive immunization using monoclonal antibodies.PMID:37665287 | PMC:PMC10485855 | DOI:10.3343/alm.2024.44.1.64
Source: Annals of Laboratory Medicine - September 4, 2023 Category: Laboratory Medicine Authors: Ahram Han Sangil Min Eun-Ah Jo Hajeong Lee Yong Chul Kim Seung Seok Han Hee Gyung Kang Yo Han Ahn Inseong Oh Eun Young Song Jongwon Ha Source Type: research
Early 3 ‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Exp Ther Med. 2023 Aug 9;26(4):462. doi: 10.3892/etm.2023.12161. eCollection 2023 Oct.ABSTRACTRemdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progress...
Source: Experimental and Therapeutic Medicine - September 4, 2023 Category: General Medicine Authors: Vasiliki Epameinondas Georgakopoulou Aikaterini Gkoufa Sotiria Makrodimitri Dimitrios Basoulis Aristeidis Tsakanikas Georgios Karamanakos Elpida Mastrogianni Pantazis M Voutsinas Demetrios A Spandidos Chrysovalantis V Papageorgiou Maria N Gamaletsou Nikol Source Type: research
As a new variant emerges, is Covid coming back to the UK?
Vaccines, available only to high-risk groups, have been brought forward as cases begin to rise and the British winter loomsThe vaccine campaign against Covid-19 hasjust been brought forward by a month in the face of changes in the disease ’s behaviour. The decision was made as the UK heads into autumn and has raised concerns that the nation faces a new wave of a disease that triggered a national lockdown three years ago. Here we look at the issues involved and scientists’ responses to the threats that lie ahead.Continue reading...
Source: Guardian Unlimited Science - September 3, 2023 Category: Science Authors: Robin McKie Tags: Coronavirus Infectious diseases Science Health Source Type: news
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
This article represents a comprehensive review of the function, structure and inhibition of SARS-CoV and -CoV-2 Mpro, including structure-activity relationships, protein-inhibitor interactions and clinical trial status.PMID:37659195 | DOI:10.1016/j.ejmech.2023.115772
Source: European Journal of Medicinal Chemistry - September 2, 2023 Category: Chemistry Authors: Xin Li Yongcheng Song Source Type: research
